🧾 What This Document Is

This is a Form 8-K filing with an attached press release (Exhibit 99.1). Think of it as a major news bulletin from Lantern Pharma to its investors. It covers their financial results for the final quarter and full year of 2025, but more importantly, it provides a detailed update on their clinical trials and business strategy. This is the kind of document that tells you if a company is hitting its milestones or facing challenges.

🏢 What The Company Does

👉 In simple terms, Lantern Pharma is a drug discovery company that uses artificial intelligence to find and develop new cancer treatments faster and cheaper. They are a clinical-stage biopharmaceutical company (meaning they're testing drugs in patients but not selling any yet). Their secret sauce is a proprietary AI platform called RADR®, which analyzes massive amounts of data to pick the right drug candidates and match them to the right patients. They focus on oncology (cancer).

💰 Financial Highlights: The Cash Runway

The money story here is about a shrinking cash pile and continued losses, which is common for biotech firms spending heavily on research.

• Cash Position: They had $10.1 million in cash, securities, etc., at year-end 2025. This is down from $24.0 million a year prior.
• The Clock is Ticking: Management estimates this cash will last until late July to mid-September 2026. 👉 This means they must secure more funding in the near future, likely through partnerships, grants, or selling more stock.
• Net Loss: They lost $17.1 million for the full year 2025. While still a big loss, it was 18% smaller than their 2024 loss of $20.8 million. This shows they're managing costs better.
• Expense Breakdown: Most of their spending ($11.5 million) went to Research & Development (R&D). General & Administrative (G&A) costs were $6.5 million.

🚀 Key Clinical Pipeline Moves

This is the core of the update. Lantern is advancing multiple AI-guided drug candidates.

• LP-300 (Phase 2 - Lung Cancer): This is their most advanced program.
  • Trial Name: HARMONIC™ trial for never-smokers with a specific type of lung cancer (a market they estimate at $4+ billion).
  • Progress: Enrollment is ongoing in the U.S., Japan, and Taiwan. They finished enrolling in Japan early.
  • Big Ask: They've submitted a plan to the FDA to change the trial design, aiming to focus on a specific patient group (EGFR exon 21 L858R mutation) and increase the treatment cycles. An FDA meeting is set for mid-May 2026.
• LP-184 (Phase 1a Complete): This drug showed promising early results.
  • Results: Achieved a 48% clinical benefit rate in very sick patients. They've established a recommended dose for future trials.
  • What's Next: They plan Phase 1b/2 trials in Triple-Negative Breast Cancer and a type of lung cancer, if they get the funding.
• LP-284 (Phase 1 - Blood Cancers): This drug received a third Orphan Drug Designation from the FDA, this time for soft tissue sarcomas. This status provides incentives like tax credits and potential market exclusivity.

⭐ Major New AI Platform: withZeta.ai

Lantern isn't just using AI for its own drugs; they're now selling it as a service.

• What it is: A new "multi-agentic AI co-scientist platform" called withZeta.ai. It's designed to help researchers across 438+ rare cancers analyze data and develop drug strategies.
• The Opportunity: This represents a near-term commercial product for Lantern. Since late December 2025, it's been in demos and beta testing with over 25 biotech companies and research centers.
• The Goal: Generate recurring revenue through subscriptions while scaling the AI platform beyond cancer into other diseases.

📦 Other Important Updates

• Starlight Therapeutics (Subsidiary): The FDA cleared their application (IND) to start a Phase 1 pediatric brain cancer trial for a drug called STAR-001. This is a key regulatory milestone.
• Fake News Clarification: The company explicitly addressed and denied a false online rumor about the CEO resigning. They confirm Panna Sharma remains President and CEO.
• Capital: They have an "at-the-market" (ATM) facility to sell up to $15.5 million in stock and sold about $1.6 million worth in 2025. This is a tool they may use to raise the cash they need.

🔮 What's Next: 2026 Catalysts

2026 is framed as a critical year for clinical and commercial milestones.

• Q2 2026: The crucial FDA meeting for LP-300 trial design.
• H1 2026: Planned starts for the LP-184 trials and a pediatric cancer trial (all subject to funding).
• Throughout 2026: Scaling the withZeta.ai platform commercially and seeking partnerships for their drugs and AI tech.
• Ongoing: Actively pursuing additional funding to extend their cash runway.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Diverse AI Pipeline: A portfolio of clinical-stage drugs with an estimated $15+ billion annual market potential.
• Validation: Multiple clinical milestones achieved and FDA designations (Orphan Drug, Rare Pediatric Disease) secured.
• New Revenue Stream: The withZeta.ai platform addresses a huge unmet need and could generate non-dilutive income.
• Cost Efficiency: Advanced drugs from idea to human trials in 2-3 years for just $1-2.5 million per program.

⚠️ Risks:

• Cash Runway: The biggest near-term risk. They will need more money by late summer 2026.
• Clinical Trial Risk: All drug candidates are still in testing. Future trials could fail or produce disappointing results.
• Partnership/Funding Dependency: Many planned 2026 trials are explicitly marked "subject to funding."
• Commercial Execution: Successfully commercializing the withZeta.ai platform is unproven and will require execution.

🧠 The Analogy

Imagine Lantern Pharma as a super-smart startup garage. They used their brilliant AI blueprint (RADR®) to build several promising prototype cars (drug candidates) for specific, tough races (cancer types). They've now driven one of them (LP-300) to the qualifying heats (Phase 2 trial). While doing this, they realized their AI blueprint itself is so valuable that they're now renting it out to other garages (withZeta.ai). The big challenge? They're running low on fuel (cash) and need to find sponsors (investors/partners) soon to keep racing and commercializing their blueprint.

📇 Key Contacts & People

• Panna Sharma: President & Chief Executive Officer
• Investor Contact:
  • Email: [email protected]
  • Phone: +1-972-277-1136

🧩 Final Takeaway

Lantern Pharma is at a pivotal point: its AI-driven drug pipeline is advancing with important clinical milestones, and it's launching a potentially lucrative AI-as-a-service product. However, the company's shrinking cash balance and the need for significant funding within the next 6 months present a major near-term hurdle that will dictate its pace of progress in 2026.